Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Intra-Cellular Ther (ITCI)

Intra-Cellular Ther (ITCI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,459,473
  • Shares Outstanding, K 94,324
  • Annual Sales, $ 83,800 K
  • Annual Income, $ -284,130 K
  • 60-Month Beta 1.28
  • Price/Sales 64.98
  • Price/Cash Flow N/A
  • Price/Book 6.87
Trade ITCI with:

Options Overview Details

View History
  • Implied Volatility 67.89% ( -2.45%)
  • Historical Volatility 81.92%
  • IV Percentile 51%
  • IV Rank 13.97%
  • IV High 157.74% on 12/14/21
  • IV Low 53.31% on 05/26/21
  • Put/Call Vol Ratio 0.35
  • Today's Volume 168
  • Volume Avg (30-Day) 379
  • Put/Call OI Ratio 0.64
  • Today's Open Interest 7,914
  • Open Int (30-Day) 11,066

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.80
  • Number of Estimates 5
  • High Estimate -0.72
  • Low Estimate -0.88
  • Prior Year -0.85
  • Growth Rate Est. (year over year) +5.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.42 +37.69%
on 05/09/22
60.64 -3.68%
on 05/19/22
+5.97 (+11.38%)
since 04/22/22
3-Month
42.42 +37.69%
on 05/09/22
66.00 -11.50%
on 04/07/22
+5.36 (+10.10%)
since 02/23/22
52-Week
28.40 +105.67%
on 08/12/21
66.00 -11.50%
on 04/07/22
+18.72 (+47.17%)
since 05/21/21

Most Recent Stories

More News
Why Intra-Cellular Therapies Stock Rose 21.4% This Week

Strong sales for the company's only marketed therapy piqued investors' interest.

ITCI : 58.41 (+0.92%)
Why Intra-Cellular Therapies Trounced the S&P 500 Today

The biotech notches an extremely convincing first-quarter earnings beat.

ITCI : 58.41 (+0.92%)
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 16.13% and 5.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ITCI : 58.41 (+0.92%)
PTN : 0.3565 (+1.83%)
Intra-Cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update

First quarter 2022 results reflect strong CAPLYTA® (lumateperone) launch in bipolar depression  First quarter 2022 CAPLYTA new and total prescriptions...

ITCI : 58.41 (+0.92%)
Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates

Atyr Pharma (LIFE) delivered earnings and revenue surprises of -29.41% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

LIFE : 2.98 (-0.67%)
ITCI : 58.41 (+0.92%)
Analysts Estimate Intra-Cellular Therapies (ITCI) to Report a Decline in Earnings: What to Look Out for

Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ITCI : 58.41 (+0.92%)
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 0% and 3.58%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

ITCI : 58.41 (+0.92%)
NGM : 13.74 (-0.79%)
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

Received FDA approval for CAPLYTA® (lumateperone) for the treatment of bipolar depression in adults. CAPLYTA is the first and only FDA-approved treatment...

ITCI : 58.41 (+0.92%)
Why Earnings Season Could Be Great for Intra-Cellular Therapies (ITCI)

Intra-Cellular Therapies (ITCI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

ITCI : 58.41 (+0.92%)
Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates

Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 16.67% and 483.65%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?...

BEAM : 34.99 (-0.57%)
ITCI : 58.41 (+0.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular...

See More

Key Turning Points

3rd Resistance Point 60.74
2nd Resistance Point 59.85
1st Resistance Point 59.13
Last Price 58.41
1st Support Level 57.52
2nd Support Level 56.63
3rd Support Level 55.91

See More

52-Week High 66.00
Last Price 58.41
Fibonacci 61.8% 51.64
Fibonacci 50% 47.20
Fibonacci 38.2% 42.76
52-Week Low 28.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar